Fremanezumab for comorbid migraine and depression

Migraine and depression often reinforce each other and make treatment more difficult. The UNITE study shows that the CGRP antibody fremanezumab significantly reduces both migraine days and depressive symptoms – even in patients with complex prior therapy. The drug proved to be effective, well tolerated and potentially doubly beneficial.